Nurix Therapeutics is trading at $21.66, down 4.69%, amid biotech-sector weakness; the XBI is down 2.04% during the regular session.
- No specific sector catalyst or clear company-specific announcement explaining the decline surfaced.
- Nurix’s Q3 earnings were anticipated for October 8, with analyst estimates of a $0.60 per-share loss and $24.35 million revenue.
- The company recently announced first-patient enrollment in a combination study, but available information does not connect that update to today’s drop.